From the, Department of Emergency Medicine, Albert Einstein College of Medicine, Bronx, NY.
Acad Emerg Med. 2020 Aug;27(8):717-724. doi: 10.1111/acem.13947. Epub 2020 Mar 24.
A fundamental challenge for emergency department (ED) clinicians is to relieve severe, acute pain while simultaneously avoiding adverse events associated with opioid analgesics. Because there is evidence that intravenous (IV) acetaminophen is an effective adjuvant analgesic in postoperative settings, we examined whether it also has a role in the ED.
This was a two-arm, double-blind randomized clinical trial. All patients received 1 mg of IV hydromorphone. Patients were then randomized to receive 1 g of IV acetaminophen or placebo. The primary outcome was the between-group difference in change in pain from baseline (before treatment) to 60 minutes after administration of study drugs, measured on an 11-point numeric rating scale (NRS).
Of 828 patients screened, 162 were enrolled and 159 had the primary outcome. Patients allocated to acetaminophen + hydromorphone had a mean decline in pain from baseline to 60 minutes of 6.2 NRS units; those receiving placebo + hydromorphone had a mean decline of 5.4, a difference of 0.8 NRS units (95% confidence interval [CI] = -0.01 to 1.8). Two patients in each group received additional analgesics in the first 60 minutes of the study. At 120 minutes the NRS pain difference was 0.6 (95% CI = -0.4 to 1.6). A total of 26.9% of patients who received acetaminophen wanted more analgesia versus 37.7% of those given placebo (difference = -10.8%, 95% CI = -24.3% to 4.4%). The incidence of adverse effects was similar in both groups.
The addition of 1 g of IV acetaminophen to 1 mg of IV hydromorphone provided neither clinically meaningful nor statistically superior analgesia than hydromorphone alone.
急诊科(ED)临床医生面临的一个基本挑战是缓解严重的急性疼痛,同时避免阿片类镇痛药相关的不良事件。由于有证据表明静脉(IV)乙酰氨基酚在术后环境中是一种有效的辅助镇痛剂,我们研究了它在 ED 中的作用。
这是一项双臂、双盲随机临床试验。所有患者均接受 1mg 静脉注射氢吗啡酮。然后将患者随机分为接受 1g 静脉注射对乙酰氨基酚或安慰剂组。主要结局是两组之间从基线(治疗前)到给予研究药物后 60 分钟时疼痛变化的差异,用 11 点数字评分量表(NRS)测量。
在筛选的 828 名患者中,有 162 名入组,159 名患者有主要结局。接受对乙酰氨基酚+氢吗啡酮治疗的患者从基线到 60 分钟时疼痛平均下降 6.2NRS 单位;接受安慰剂+氢吗啡酮治疗的患者平均下降 5.4 个单位,差异为 0.8NRS 单位(95%置信区间 [CI]:-0.01 至 1.8)。两组各有 2 名患者在研究的前 60 分钟内接受了额外的镇痛剂。在 120 分钟时,NRS 疼痛差异为 0.6(95%CI:-0.4 至 1.6)。接受对乙酰氨基酚治疗的患者中有 26.9%的人希望增加镇痛剂,而接受安慰剂治疗的患者中有 37.7%的人希望增加镇痛剂(差异为-10.8%,95%CI:-24.3%至 4.4%)。两组的不良反应发生率相似。
与单独使用氢吗啡酮相比,静脉注射 1 克对乙酰氨基酚联合 1 毫克静脉注射氢吗啡酮既不能提供临床上有意义的镇痛效果,也不能提供统计学上的优势。